[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20110414T1 - Indoli i njihova uporaba u liječenju - Google Patents

Indoli i njihova uporaba u liječenju Download PDF

Info

Publication number
HRP20110414T1
HRP20110414T1 HR20110414T HRP20110414T HRP20110414T1 HR P20110414 T1 HRP20110414 T1 HR P20110414T1 HR 20110414 T HR20110414 T HR 20110414T HR P20110414 T HRP20110414 T HR P20110414T HR P20110414 T1 HRP20110414 T1 HR P20110414T1
Authority
HR
Croatia
Prior art keywords
fluoro
alkyl
chloro
phenyl
optionally substituted
Prior art date
Application number
HR20110414T
Other languages
English (en)
Inventor
Hynd George
Gary Montana John
Finch Harry
Arienzo Rosa
Avitabile-Woo Barbara
Domostoj Mathias
Original Assignee
Pulmagen Therapeutics (Asthma) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0724429A external-priority patent/GB0724429D0/en
Priority claimed from GB0806083A external-priority patent/GB0806083D0/en
Priority claimed from GB0814910A external-priority patent/GB0814910D0/en
Application filed by Pulmagen Therapeutics (Asthma) Limited filed Critical Pulmagen Therapeutics (Asthma) Limited
Publication of HRP20110414T1 publication Critical patent/HRP20110414T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Spoj {5-fluoro-2-metil-3-[3-(piridin-2-sulfonil)tiofen-2-ilmetil]indol-1-il}octena kiselina ili njena farmaceutski prihvatljiva sol. Patent sadrži još 3 patentna zahtjeva.

Claims (4)

1. Spoj {5-fluoro-2-metil-3-[3-(piridin-2-sulfonil)tiofen-2-ilmetil]indol-1-il}octena kiselina ili njena farmaceutski prihvatljiva sol.
2. Farmaceutska smjesa koja sadrži spoj prema zahtjevu 1 i farmaceutski prihvatljivi nosač.
3. Spoj prema zahtjevu 1, za liječenje astme, kronične opstruktivne plućne bolesti, rinitisa, alergijskog sindroma dišnih puteva ili alergijskog rinobronhitisa.
4. Spoj prema zahtjevu 1, za liječenje psorijaze, atopijskog i ne-atopijskog dermatitisa, Crohnove bolesti, ulceroznog kolitisa ili iritabilne bolesti crijeva.
HR20110414T 2007-12-14 2011-06-03 Indoli i njihova uporaba u liječenju HRP20110414T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0724429A GB0724429D0 (en) 2007-12-14 2007-12-14 Compounds
GB0806083A GB0806083D0 (en) 2008-04-03 2008-04-03 Compounds
GB0814910A GB0814910D0 (en) 2008-08-14 2008-08-14 Compounds
PCT/GB2008/004107 WO2009077728A1 (en) 2007-12-14 2008-12-12 Indoles and their therapeutic use

Publications (1)

Publication Number Publication Date
HRP20110414T1 true HRP20110414T1 (hr) 2011-08-31

Family

ID=40328483

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20110414T HRP20110414T1 (hr) 2007-12-14 2011-06-03 Indoli i njihova uporaba u liječenju
HRP20120554AT HRP20120554T1 (hr) 2007-12-14 2012-07-06 Indoli i njihova terapijska uporaba

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20120554AT HRP20120554T1 (hr) 2007-12-14 2012-07-06 Indoli i njihova terapijska uporaba

Country Status (22)

Country Link
US (2) US8394836B2 (hr)
EP (2) EP2327693B9 (hr)
JP (1) JP5327762B2 (hr)
CN (1) CN101970405A (hr)
AT (1) ATE502920T1 (hr)
AU (1) AU2008337342B2 (hr)
BR (1) BRPI0820872A2 (hr)
CA (1) CA2707785C (hr)
CY (2) CY1111585T1 (hr)
DE (1) DE602008005796D1 (hr)
DK (2) DK2229358T3 (hr)
EA (1) EA017573B1 (hr)
ES (1) ES2386340T3 (hr)
HR (2) HRP20110414T1 (hr)
IL (1) IL206087A (hr)
MX (1) MX2010006341A (hr)
NZ (1) NZ585888A (hr)
PL (2) PL2229358T3 (hr)
PT (2) PT2327693E (hr)
SI (2) SI2229358T1 (hr)
WO (1) WO2009077728A1 (hr)
ZA (1) ZA201003872B (hr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
DK2046740T3 (da) 2006-07-22 2012-08-20 Oxagen Ltd Forbindelser med CRTH2-antagonistisk virkning
CN101932571B (zh) * 2008-01-18 2014-04-23 奥克萨根有限公司 具有crth2拮抗活性的化合物
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2009093029A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
RU2562255C2 (ru) 2010-03-22 2015-09-10 Актелион Фармасьютиклз Лтд Производные 3-(гетероариламино)-1,2,3,4-тетрагидро-9н-карбазола и их применение в качестве модуляторов рецепторов простагландина d2
WO2012009134A1 (en) * 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
JP5964945B2 (ja) 2011-04-14 2016-08-03 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd 7−(ヘテロアリ−ル−アミノ)−6,7,8,9−テトラヒドロピリド[1,2−a]インド−ル酢酸誘導体及びプロスタグランジンD2受容体調節剤としてのそれらの使用
MX350516B (es) 2011-11-17 2017-09-08 Kbp Biosciences Co Ltd Compuestos de anillo fusionado que contienen nitrogeno como antagonistas crth2.
JP2015500326A (ja) * 2011-12-16 2015-01-05 アトピックス テラピューティクス リミテッド 好酸球性食道炎の治療のためのcrth2拮抗薬およびプロトンポンプ阻害薬の組み合わせ
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
GB201322273D0 (en) * 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
PT3119779T (pt) 2014-03-17 2018-10-19 Idorsia Pharmaceuticals Ltd Derivados de ácido azaindol acético e sua utilização como modeladores de recetor d2 de prostaglandina
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
CN106536516B (zh) * 2014-06-09 2019-09-03 住友化学株式会社 用于制备吡啶化合物的方法
CA2993893A1 (en) 2015-09-15 2017-03-23 Idorsia Pharmaceuticals Ltd Crystalline forms
TWI726968B (zh) 2016-01-07 2021-05-11 開曼群島商Cs醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
US11753626B2 (en) 2016-03-09 2023-09-12 Beijing Percans Oncology Co., Ltd. Tumor cell suspension cultures and related methods
JP7044754B2 (ja) * 2016-07-21 2022-03-30 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Crth2阻害剤としてのインドール誘導体
JP2020533595A (ja) 2017-09-13 2020-11-19 プロジェニティ, インコーポレイテッド 子癇前症バイオマーカならびに関連するシステムおよび方法
CN109096186B (zh) * 2018-09-29 2020-08-04 中南大学 一种2-芳磺酰基喹啉衍生物的合成方法
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN113425714B (zh) * 2021-08-04 2022-04-26 华南师范大学 吲哚乙酸在制备防治慢性阻塞性肺病药物中的应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508583A (ja) 1995-07-06 1999-07-27 ゼネカ・リミテッド ペプチド系のフィブロネクチン阻害薬
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
JP2001163899A (ja) 1999-12-09 2001-06-19 Natl Inst Of Sericultural & Entomological Science 機能性絹フィブロインの製造方法とその利用
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
WO2003022813A1 (fr) 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Derives indole, methode de fabrication et medicaments renfermant lesdits derives en tant que principe actif
WO2003053930A1 (en) 2001-12-20 2003-07-03 Bayer Healthcare Ag 1,4-dihydro-1,4-diphenylpyridine derivatives
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
US7534897B2 (en) 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
AU2003231513A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Pgd2 receptor antagonist
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
EA011385B1 (ru) 2002-10-04 2009-02-27 Миллениум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1413306A1 (en) 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
EP1556356B1 (en) 2002-10-21 2006-05-31 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as crth2 antagonists
NZ541234A (en) 2002-12-20 2008-06-30 Amgen Inc Asthma and allergic inflammation modulators
EP1435356A1 (en) 2003-01-06 2004-07-07 Warner-Lambert Company LLC Quinoline derivatives as CRTH2 antagonists
EP1600440A1 (en) 2003-03-06 2005-11-30 Ono Pharmaceutical Co., Ltd. Indole derivative compounds and drugs containing the compounds as the active ingredient
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
US20050038070A1 (en) 2003-07-09 2005-02-17 Amgen Inc. Asthma and allergic inflammation modulators
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
AU2004283139A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB2407318A (en) 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
ES2345662T3 (es) 2004-03-11 2010-09-29 Actelion Pharmaceuticals Ltd. Derivados de acido indol-1-il-acetico.
CA2561564A1 (en) 2004-04-07 2005-10-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20050242153A1 (en) 2004-04-20 2005-11-03 Acco Brands, Inc. Stapler
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
WO2005115382A1 (en) 2004-05-29 2005-12-08 7Tm Pharma A/S Crth2 receptor ligands for medicinal uses
US7405215B2 (en) 2004-09-21 2008-07-29 Wyeth Indole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
SI1817282T1 (sl) 2004-11-23 2011-10-28 Astrazeneca Ab Derivati fenoksiocetne kisline, uporabni za zdravljenje respiratornih bolezni
GB0427381D0 (en) 2004-12-14 2005-01-19 Novartis Ag Organic compounds
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
UA90706C2 (ru) 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
GB0510584D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
GB0510585D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
ES2399061T3 (es) 2005-09-30 2013-03-25 Pulmagen Therapeutics (Asthma) Limited Quinolinas y su uso terapéutico
GB0521275D0 (en) 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
WO2007062678A1 (en) 2005-11-29 2007-06-07 7Tm Pharma A/S Phenoxyacetic acid derivatives as crth2 receptor ligands
GB0524428D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
GB0525141D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
EP2125722A2 (en) 2006-05-26 2009-12-02 AstraZeneca AB Bi-aryl or aryl-heteroaryl substituted indoles
GB0611695D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
DK2046740T3 (da) * 2006-07-22 2012-08-20 Oxagen Ltd Forbindelser med CRTH2-antagonistisk virkning
EA200970590A1 (ru) 2006-12-21 2009-12-30 Арджента Дискавери Лимитед Антагонисты crth2
US20100137300A1 (en) 2007-03-21 2010-06-03 George Hynd Indolizine Acetic Acid Derivatives as CRTH2 Antagonists
BRPI0721516A2 (pt) 2007-03-29 2013-01-15 Argenta Discovery Ltd derivados de quinolina como ligantes de receptor crth2
CA2680682C (en) 2007-04-04 2015-05-26 Argenta Discovery Limited Quinolines and their therapeutic use
GB0722203D0 (en) * 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds

Also Published As

Publication number Publication date
WO2009077728A1 (en) 2009-06-25
EA017573B1 (ru) 2013-01-30
DK2327693T3 (da) 2012-08-13
PL2327693T3 (pl) 2012-11-30
SI2229358T1 (sl) 2011-10-28
DE602008005796D1 (de) 2011-05-05
MX2010006341A (es) 2010-08-02
BRPI0820872A2 (pt) 2015-07-21
SI2327693T1 (sl) 2012-09-28
CA2707785C (en) 2015-11-03
US8394836B2 (en) 2013-03-12
PT2229358E (pt) 2011-06-29
EP2229358B1 (en) 2011-03-23
CY1111585T1 (el) 2015-10-07
HRP20120554T1 (hr) 2012-07-31
AU2008337342A1 (en) 2009-06-25
PL2229358T3 (pl) 2011-09-30
IL206087A0 (en) 2010-11-30
JP2011506415A (ja) 2011-03-03
EA201070731A1 (ru) 2011-02-28
ZA201003872B (en) 2011-08-31
ES2386340T3 (es) 2012-08-17
IL206087A (en) 2016-05-31
EP2327693B1 (en) 2012-06-20
EP2327693B9 (en) 2012-10-24
EP2229358A1 (en) 2010-09-22
CY1113179T1 (el) 2016-04-13
ATE502920T1 (de) 2011-04-15
US20130225617A1 (en) 2013-08-29
PT2327693E (pt) 2012-07-24
JP5327762B2 (ja) 2013-10-30
CA2707785A1 (en) 2009-06-25
US20110071175A1 (en) 2011-03-24
NZ585888A (en) 2012-02-24
AU2008337342B2 (en) 2012-05-24
CN101970405A (zh) 2011-02-09
EP2327693A1 (en) 2011-06-01
DK2229358T3 (da) 2011-07-04

Similar Documents

Publication Publication Date Title
HRP20110414T1 (hr) Indoli i njihova uporaba u liječenju
HRP20140705T1 (hr) Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
RS53021B (en) INDOLIC, AZAINDOL AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES
PE20141372A1 (es) Nuevos derivados dihidroquinolina-2-ona
ES2615742T3 (es) Benzamidas sustituidas con actividad hacia receptores EP4
NO20084350L (no) Heterocykliske amider til anvendelse som farmasoytika
BR112014015832A2 (pt) derivados heterocíclicos como receptores associados com aminas vistigiais (taars)
RS53684B1 (en) PROSTACYCLINE (PGI2) MODULATORS FOR RECIPES USEFUL IN TREATMENT OF PGI2-related DISORDERS
NO20074324L (no) Substituerte arylamin sammensetniger og deres andvendelse som 5-HT6 modulatorer
AU2007296964B2 (en) Nicotinic acid derivatives as modulators of metabotropic glutanate receptors
RS54183B1 (en) PIRAZOLE DERIVATIVES
MX2009008509A (es) Compuesto de anillo puenteado-aza.
EA201170099A1 (ru) Замещенные пиримидин-4-оновые производные
NO20066049L (no) Substituerte tiazoleddiksyrer som CRTH2-ligandere
MX2009013115A (es) Derivados de prolinamida como antagonistas de nk3.
ATE532780T1 (de) Chinoline und ihre therapeutische verwendung
BR112013010558A2 (pt) derivados de di-hidro-oxazol-2-amina
NO20071230L (no) Oksazolidinoner inneholdende oksindoler som antibakterielle midler
NO20034471D0 (no) Aryl (eller heteroaryl)-azolylkarbinolderivater for behandling av respiratoriske sykdommer
Polozov et al. A general approach to indole-7-yl derivatives of isoxazole, oxadiazole, thiadiazole and pyrazole
AR056303A1 (es) Pirrol(2,3-d)imidazoles para el tratamiento de desordenes hiperproliferativos. composiciones farmaceuticas
Zhong et al. Progress in the Synthesis of 5-Aminothiazole Derivatives
AR096565A1 (es) Inhibidores de la pde10a para el tratamiento de diabetes tipo ii
BR112015018930B1 (pt) Composto, uso do composto e composição farmacêutica
TN2011000138A1 (en) Novel pyrazolone derivatives and their use as pd4 inhibitors